Resources
At Lynx Dx, we’re dedicated to providing providers and families the resources they need to navigate the complexities of prostate cancer. Here you’ll find news, press releases, blog articles, events, research, and other content to support a care journey.
Why You Want Your Medical Test to be Validated and Based on Peer-Reviewed Research
MyProstateScore 2.0 is a clinically validated prostate cancer test based on “peer reviewed” research. What do these terms mean for men with a high PSA?
Lynx Dx Wins Award as One of ’50 Companies to Watch’ by Michigan Celebrates Small Business
ANN ARBOR, Mich.– Lynx Dx, a leader in innovative diagnostic solutions, has been recognized as one [...]
Peer-Reviewed Research Published in JAMA Oncology Validates the Efficacy of MPS2
New peer-reviewed research published in the Journal of the American Medical Association (JAMA) Oncology validates the [...]
Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer
Lynx Dx's Biomarker Test Offers Market-Leading Accuracy in Prostate Cancer Risk Assessment ANN ARBOR, Mich., April [...]
Revealing the Latest Prostate Cancer Insights and Innovation at AUA2024!
MyProstateScore 2.0 (MPS2) is the only biomarker test with 99% negative predictive value (NPV) for the prediction [...]
A Brief Glossary of Terms Related to Prostate Cancer
Prostate cancer awareness is key for men’s health. Get comfortable with terms like “biopsy,” “PSA,” “clinically significant” and “grade group.”
The Importance of Community Outreach and Involvement in Black Men’s Fight Against Prostate Cancer
A community-based approach to educating Black men about prostate cancer and increasing access to care can help close the health disparity gap.
How a Biomarker Test Can Help When a Prostate Biopsy is Negative
Men who’ve had a negative prostate biopsy and still have high PSA are a unique group. Biomarker screening could help these patients avoid a repeat biopsy.
Lynx Dx Leader Featured in Chief Healthcare Executive
The article calls for action to address prostate cancer health disparities. Spencer Heaton, MD, MBA, Chief Medical [...]